PGC-1a rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function

Science Translational Medicine

Volumn 4, Issue 142, 2012, Pages

  Tsunemi, Taiji ^a   Ashe, Travis D ^a   Morrison, Bradley E ^a   Soriano, Kathryn R ^b   Au, Jonathan ^b   Roque, Ruben A Vázquez ^c   Lazarowski, Eduardo R ^d   Damian, Vincent A ^b   Masliah, Eliezer ^c,e   La Spada, Albert R ^{a,e,f,g,h,i,j}  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ RADY CHILDREN'S HOSPITAL   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; PEPTIDE; POLYGLUTAMINE; PPARGC1A PROTEIN, MOUSE; REACTIVE OXYGEN METABOLITE; TCFEB PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; GENE; GENE FREQUENCY; HUNTINGTIN GENE; HUNTINGTON CHOREA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TARGETING; TRANSCRIPTION FACTOR EB GENE; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; MITOCHONDRION; NERVE DEGENERATION; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NERVE DEGENERATION; OXIDATIVE STRESS; PEPTIDES; PHENOTYPE; PROTEIN STRUCTURE, QUATERNARY; REACTIVE OXYGEN SPECIES; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84863923855     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003799     Document Type: Article

References (62)

1. M. A. Nance, Clinical aspects of CAG repeat diseases. Brain Pathol. 7, 881-900 (1997).
2. J. P. Vonsattel, R. H. Myers, T. J. Stevens, R. J. Ferrante, E. D. Bird, E. P. Richardson Jr., Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577 (1985).
3. Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
4. A. R. La Spada, J. P. Taylor, Repeat expansion disease: Progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 11, 247-258 (2010).
5. H. L. Paulson, Protein fate in neurodegenerative proteinopathies: Polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet. 64, 339-345 (1999).
6. Y. Trottier, Y. Lutz, G. Stevanin, G. Imbert, D. Devys, G. Cancel, F. Saudou, C. Weber, G. David, L. Tora, Y. Agid, A. Brice, J. L. Mandel, Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403-406 (1995).
7. M. F. Beal, B. T. Hyman, W. Koroshetz, Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16, 125-131 (1993).
8. M. F. Beal, E. Brouillet, B. G. Jenkins, R. J. Ferrante, N. W. Kowall, J. M. Miller, E. Storey, R. Srivastava, B. R. Rosen, B. T. Hyman, Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192 (1993).
9. N. A. Aziz, J. M. van der Burg, G. B. Landwehrmeyer, P. Brundin, T. Stijnen, R. A. Roos, Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71, 1506-1513 (2008).
10. L. B. Menalled, M. F. Chesselet, Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39 (2002).
11. S. E. Browne, M. F. Beal, The energetics of Huntington's disease. Neurochem. Res. 29, 531-546 (2004).
12. I. S. Seong, E. Ivanova, J. M. Lee, Y. S. Choo, E. Fossale, M. Anderson, J. F. Gusella, J. M. Laramie, R. H. Myers, M. Lesort, M. E. MacDonald, HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871-2880 (2005).
13. Y. S. Choo, G. V. Johnson, M. MacDonald, P. J. Detloff, M. Lesort, Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407-1420 (2004).
14. A. L. Orr, S. Li, C. E. Wang, H. Li, J. Wang, J. Rong, X. Xu, P. G. Mastroberardino, J. T. Greenamyre, X. J. Li, N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28, 2783-2792 (2008).
15. A. V. Panov, C. A. Gutekunst, B. R. Leavitt, M. R. Hayden, J. R. Burke, W. J. Strittmatter, J. T. Greenamyre, Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736 (2002).
16. B. E. Riley, H. T. Orr, Polyglutamine neurodegenerative diseases and regulation of transcription: Assembling the puzzle. Genes Dev. 20, 2183-2192 (2006).
17. G. Schilling, M. W. Becher, A. H. Sharp, H. A. Jinnah, K. Duan, J. A. Kotzuk, H. H. Slunt, T. Ratovitski, J. K. Cooper, N. A. Jenkins, N. G. Copeland, D. L. Price, C. A. Ross, D. R. Borchelt, Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407 (1999).
18. P. Weydt, V. V. Pineda, A. E. Torrence, R. T. Libby, T. F. Satterfield, E. R. Lazarowski, M. L. Gilbert, G. J. Morton, T. K. Bammler, A. D. Strand, L. Cui, R. P. Beyer, C. N. Easley, A. C. Smith, D. Krainc, S. Luquet, I. R. Sweet, M. W. Schwartz, A. R. La Spada, Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362 (2006).
19. P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, B. M. Spiegelman, A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829-839 (1998).
20. J. St-Pierre, S. Drori, M. Uldry, J. M. Silvaggi, J. Rhee, S. Jäger, C. Handschin, K. Zheng, J. Lin, W. Yang, D. K. Simon, R. Bachoo, B. M. Spiegelman, Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408 (2006).
21. Z. Wu, P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cinti, B. Lowell, R. C. Scarpulla, B. M. Spiegelman, Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115-124 (1999).
22. T. C. Leone, J. J. Lehman, B. N. Finck, P. J. Schaeffer, A. R. Wende, S. Boudina, M. Courtois, D. F. Wozniak, N. Sambandam, C. Bernal-Mizrachi, Z. Chen, J. O. Holloszy, D. M. Medeiros, R. E. Schmidt, J. E. Saffitz, E. D. Abel, C. F. Semenkovich, D. P. Kelly, PGC-1α deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3, e101 (2005).
23. J. Lin, P. H. Wu, P. T. Tarr, K. S. Lindenberg, J. St-Pierre, C. Y. Zhang, V. K. Mootha, S. Jäger, C. R. Vianna, R. M. Reznick, L. Cui, M. Manieri, M. X. Donovan, Z. Wu, M. P. Cooper, M. C. Fan, L. M. Rohas, A. M. Zavacki, S. Cinti, G. I. Shulman, B. B. Lowell, D. Krainc, B. M. Spiegelman, Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119, 121-135 (2004).
24. L. Cui, H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese, D. Krainc, Transcriptional repression of PGC-1a by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59-69 (2006).
25. R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, A. Ciammola, F. Squitieri, M. F. Beal, Impaired PGC-1α function in muscle in Huntington's disease. Hum. Mol. Genet. 18, 3048-3065 (2009).
26. J. T. Greenamyre, Huntington's disease - Making connections. N. Engl. J. Med. 356, 518-520 (2007).
27. C. Settembre, C. DiMalta, V. A. Polito, M. Garcia Arencibia, F. Vetrini, S. Erdin, S. U. Erdin, T. Huynh, D. Medina, P. Colella, M. Sardiello, D. C. Rubinsztein, A. Ballabio, TFEB links autophagy to lysosomal biogenesis. Science 332, 1429-1433 (2011).
28. L. K. Russell, C. M. Mansfield, J. J. Lehman, A. Kovacs, M. Courtois, J. E. Saffitz, D. M. Medeiros, M. L. Valencik, J. A. McDonald, D. P. Kelly, Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor g coactivator-1a promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ. Res. 94, 525-533 (2004).
29. G. Belteki, J. Haigh, N. Kabacs, K. Haigh, K. Sison, F. Costantini, J. Whitsett, S. E. Quaggin, A. Nagy, Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 33, e51 (2005).
30. S. O'Gorman, N. A. Dagenais, M. Qian, Y. Marchuk, Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 94, 14602-14607 (1997).
31. M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, S. Finkbeiner, Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
32. J. L. Wacker, M. H. Zareie, H. Fong, M. Sarikaya, P. J. Muchowski, Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol. 11, 1215-1222 (2004).
33. D. C. Rubinsztein, The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786 (2006).
34. P. J. Muchowski, K. Ning, C. D'Souza-Schorey, S. Fields, Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. U.S.A. 99, 727-732 (2002).
35. R. Kayed, E. Head, F. Sarsoza, T. Saing, C. W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J. L. Thompson, S. Rasool, T. Gurlo, P. Butler, C. G. Glabe, Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18 (2007).
36. M. F. Beal, R. J. Ferrante, Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373-384 (2004).
37. F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V. C. Wheeler, A. H. Sharp, F. Persichetti, E. Cattaneo, M. E. MacDonald, Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum. Mol. Genet. 9, 2799-2809 (2000).
38. S. Okamoto, M. A. Pouladi, M. Talantova, D. Yao, P. Xia, D. E. Ehrnhoefer, R. Zaidi, A. Clemente, M. Kaul, R. K. Graham, D. Zhang, H. S. Vincent Chen, G. Tong, M. R. Hayden, S. A. Lipton, Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15, 1407-1413 (2009).
39. J. E. Young, G. A. Garden, R. A. Martinez, F. Tanaka, C. M. Sandoval, A. C. Smith, B. L. Sopher, A. Lin, K. H. Fischbeck, L. M. Ellerby, R. S. Morrison, J. P. Taylor, A. R. La Spada, Polyglutamineexpanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J. Neurosci. 29, 1987-1997 (2009).
40. C. J. Cummings, E. Reinstein, Y. Sun, B. Antalffy, Y. Jiang, A. Ciechanover, H. T. Orr, A. L. Beaudet, H. Y. Zoghbi, Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
41. J. M. Warrick, H. Y. Chan, G. L. Gray-Board, Y. Chai, H. L. Paulson, N. M. Bonini, Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23, 425-428 (1999).
42. J. P. Taylor, J. Hardy, K. H. Fischbeck, Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
43. J. Kaplan, Spinocerebellar ataxias due to mitochondrial defects. Neurochem. Int. 40, 553-557 (2002).
44. E. A. Schon, S. Santra, F. Pallotti, M. E. Girvin, Pathogenesis of primary defects in mitochondrial ATP synthesis. Semin. Cell. Dev. Biol. 12, 441-448 (2001).
45. M. T. Lin, M. F. Beal, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795 (2006).
46. B. Zheng, Z. Liao, J. J. Locascio, K. A. Lesniak, S. S. Roderick, M. L. Watt, A. C. Eklund, Y. Zhang-James, P. D. Kim, M. A. Hauser, E. Grünblatt, L. B. Moran, S. A. Mandel, P. Riederer, R. M. Miller, H. J. Federoff, U. Wüllner, S. Papapetropoulos, M. B. Youdim, I. Cantuti-Castelvetri, A. B. Young, J. M. Vance, R. L. Davis, J. C. Hedreen, C. H. Adler, T. G. Beach, M. B. Graeber, F. A. Middleton, J. C. Rochet, C. R. Scherzer; Global PD Gene Expression (GPEX) Consortium, PGC-1a, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73 (2010).
47. J. H. Shin, H. S. Ko, H. Kang, Y. Lee, Y. I. Lee, O. Pletinkova, J. C. Troconso, V. L. Dawson, T. M. Dawson, PARIS (ZNF746) repression of PGC-1a contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702 (2011).
48. S. E. Browne, R. J. Ferrante, M. F. Beal, Oxidative stress in Huntington's disease. Brain Pathol. 9, 147-163 (1999).
49. J. Clark, E. L. Clore, K. Zheng, A. Adame, E. Masliah, D. K. Simon, Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in a-synuclein overexpressing mice. PLoS One 5, e12333 (2010).
50. E. Wong, A. M. Cuervo, Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805-811 (2010).
51. B. Friguet, E. R. Stadtman, L. I. Szweda, Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J. Biol. Chem. 269, 21639-21643 (1994).
52. K. Okada, C. Wangpoengtrakul, T. Osawa, S. Toyokuni, K. Tanaka, K. Uchida, 4-Hydroxy- 2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 274, 23787-23793 (1999).
53. A. L. Bulteau, K. C. Lundberg, K. M. Humphries, H. A. Sadek, P. A. Szweda, B. Friguet, L. I. Szweda, Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276, 30057-30063 (2001).
54. K. A. Malkus, E. Tsika, H. Ischiropoulos, Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: How neurons are lost in the Bermuda triangle. Mol. Neurodegener. 4, 24 (2009).
55. M. Sardiello, M. Palmieri, A. di Ronza, D. L. Medina, M. Valenza, V. A. Gennarino, C. Di Malta, F. Donaudy, V. Embrione, R. S. Polishchuk, S. Banfi, G. Parenti, E. Cattaneo, A. Ballabio, A gene network regulating lysosomal biogenesis and function. Science 325, 473-477 (2009).
56. Y. Batlevi, A. R. La Spada, Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol. Dis. 43, 46-51 (2011).
57. D. P. Kelly, R. C. Scarpulla, Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18, 357-368 (2004).
58. G. A. Garden, R. T. Libby, Y. H. Fu, Y. Kinoshita, J. Huang, D. E. Possin, A. C. Smith, R. A. Martinez, G. C. Fine, S. K. Grote, C. B. Ware, D. D. Einum, R. S. Morrison, L. J. Ptacek, B. L. Sopher, A. R. La Spada, Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous Purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci. 22, 4897-4905 (2002).
59. A. R. La Spada, Y. Fu, B. L. Sopher, R. T. Libby, X. Wang, L. Y. Li, D. D. Einum, J. Huang, D. E. Possin, A. C. Smith, R. A. Martinez, K. L. Koszdin, P. M. Treuting, C. B. Ware, J. B. Hurley, L. J. Ptácek, S. Chen, Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31, 913-927 (2001).
60. O. F. Sonmez, E. Odaci, O. Bas, S. Colakoglu, B. Sahin, S. Bilgic, S. Kaplan, A stereological study of MRI and the Cavalieri principle combined for diagnosis and monitoring of brain tumor volume. J. Clin. Neurosci. 17, 1499-1502 (2010).
61. K. Ubhi, E. Rockenstein, M. Mante, C. Inglis, A. Adame, C. Patrick, K. Whitney, E. Masliah, Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 30, 6236-6246 (2010).
62. I. P. Everall, R. DeTeresa, R. Terry, E. Masliah, Comparison of two quantitative methods for the evaluation of neuronal number in the frontal cortex in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 1202-1206 (1997).